T2 hypointense rims and ring-enhancing lesions in MS

Multiple Sclerosis

Volumn 16, Issue 11, 2010, Pages 1317-1325

  Llufriu, Sara ^a   Pujol, Teresa ^a   Blanco, Yolanda ^a   Hankiewicz, Karolina ^a   Squarcia, Mattia ^a   Berenguer, Joan ^a   Villoslada, Pablo ^b   Graus, Francesc ^a   Saiz, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

diffusion weighted imaging; magnetic resonance imaging; Multiple sclerosis; ring enhancing lesions; T2 hypointensity

Indexed keywords

GADOLINIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN DAMAGE; CLINICAL EVALUATION; CLINICAL PRACTICE; COHORT ANALYSIS; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; BRAIN; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78449266518     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510377905     Document Type: Article

References (37)

1. Morgen K., Jeffries NO, Stone R., et al. Ring-enhancement in multiple sclerosis: marker of disease severity. Mult Scler 2001 ; 7: 167-171.
2. He J., Grossman RI, Ge Y. and Mannon J. Enhancing patterns in multiple sclerosis: Evolution and persistence. Am J Neuroradiol 2000 ; 22: 664-669.
3. Zivadinov R., Gabnato F., Nasuelli D., et al. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci 2004 ; 223: 185-193.
4. Brück W., Neubert K., Berger T. and Weber JF Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination-possible markers for an antibody-mediated process. Mult Scler 2001 ; 7: 173-177.
5. König FB, Wildemann B., Nessler S., et al. Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 2008 ; 65: 1527-1532.
6. Schwartz KM, Erickson BJ and Lucchinetti C. Pattern of T2 hypointensity associated with ring-enhancing brain lesions can help to differentiate pathology. Neuroradiology 2006 ; 48: 143-149.
7. Lucchinetti CF, Altintas A., Wegner C., et al. Magnetic Resonance Imaging Correlates of Multiple Sclerosis Pathologic Subtypes. Ann Neurol 2003 ; 54 (Suppl 7): S37.
8. Lucchinetti CF, Gavrilova RH, Metz I., et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008 ; 131: 1759-1775.
9. Scanderbeg A., Sabatini U., Fasano F., et al. Diffusion of water in large demyelinating lesions: a follow-up study. Neuroradiol 2002 ; 44: 764-767.
10. Roychowdhury S., Maldijan JA and Grossman RI Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions. Am J Neuroradiol 2000 ; 21: 869-874.
11. Rovaris M., Gass A., Bammer R., et al. Diffusion MRI in multiple sclerosis. Neurology 2005 ; 65: 1526-1532.
12. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
13. Gà3mez-Choco MJ, Iranzo A., Blanco Y., Graus F., Santamarà-a J. and Saiz A. Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis. Mult Scler 2007 ; 13: 805-808.
14. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997 ; 120: 1085-1096.
15. Casado V., Martà-nez-Yélamos S., Martà-nez- Yélamos A., et al. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res 2006 ; 6: 143.
16. Malhotra HS, Jain KK, Agarwal A., et al. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler 2009 ; 15: 193-203.
17. Yetkin Z. and Haughton VM Atypical demyelinating lesions in patients with multiple sclerosis. Neuroradiology 1995 ; 37: 284-286.
18. LeVine SM Iron deposits in multiple sclerosis and Alzheimers disease brains. Brain Res 1997 ; 760: 298-303.
19. Craelius W., Migdal MW, Luessenhop CP, et al. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 1982 ; 106: 397-399.
20. Wattjes MP and Barkhof F. High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiol 2009 ; 51: 279-302.
21. Kollia K., Maderwald S., Putzki N., et al. First clinical study on Ultra-High-Field MR imaging in patients with multiple sclerosis: comparison of 1.5 T and 7 t Am J Neuroradiol 2009 ; 30: 699-702.
22. Hammond KE, Metcalf M., Carvajal L., et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008 ; 64: 707-713.
23. Seewann A., Enzinger C., Filippi M., et al. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain. A review of reported findings. J Neurol 2008 ; 255: 1-10.
24. Brück W., Bitsch A., Kolenda H., Brück Y., Stiefel M. and Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997 ; 42: 783-793.
25. Wolinsky JS PROMiSe Trial Study Group. The PROMiSe trial: baseline data review and progress report. Mult Scler 2004 ; 10: S65-S72.
26. Revesz T., Kidd D., Thompson AJ, Barnard RO and McDonald WI A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994 ; 117: 759-765.
27. Molyneux PD, Filippi M., Bakhof F., et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998 ; 43: 332-339.
28. Kappos L., Moeri D., Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999 ; 353: 964-969.
29. Daumer M., Neuhaus A., Morrissey S., Hintzen R. and Ebers GC MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009 ; 72: 705-710.
30. Van den Elskamp I., Lembcke J., Dattola V., et al. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. Mult Scler 2008 ; 14: 764-769.
31. Leist TP, Gobbini MI, Frank JA and McFarland HF Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001 ; 58: 57-60.
32. Petrella JR, Grossman RI, McGowan JC, Campbell G. and Cohen JA Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect. Am J Neuroradiol 1996 ; 17: 1041-1049.
33. Rovira A., Alonso J., Cucurella G., et al. Evolution of multiple sclerosis lesions on serial contrast-enhaced T1-weighted and magnetization-transfer MR images. Am J Neuroradiol 1999 ; 20: 1939-1945.
34. Tievsky AL, Ptak T. and Farkas J. Investigation of apparent diffusion coefficient and diffusion tensor anisotropy in acute and chronic multiple sclerosis lesions. Am J Neuroradiol 1999 ; 20: 1491-1499.
35. Gass A., Niendorf T. and Hirsch JG Acute and chronic changes of the apparent diffusion coefficient in neurological disorders-biophysical mechanisms and possible underlying histopathology. J Neurol Sci 2001 ; 186: S15-S23.
36. Rovira A., Pericot I., Alonso J., Rio J., Grive E. and Montalban X. Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. Am J Neuroradiol 2002 ; 23: 989-994.
37. Rosso C., Remy P., Creange A., Brugieres P., Cesaro P. and Hosseini H. Diffusion-weighted MR imaging characteristics of an acute strokelike form of multiple sclerosis. Am J Neuroradiol 2006 ; 27: 1006-1008.